Genmab A/S vs Regeneron Pharmaceuticals
GMAB and REGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How GMAB and REGN compare
Regeneron Pharmaceuticals pays a dividend yielding 0.39%; Genmab A/S does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 0 for Genmab A/S), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | GMAB | REGN |
|---|---|---|
| Size and price | ||
| Market cap | – | $98.8B |
| Share price | $51.37 | $955.47 |
| Change, 1 year | 68.6% | 40.2% |
| Change, 5 years | 23.9% | 46.4% |
| Beta (5Y) | 0.73 | 0.62 |
| Employees | 3,029 | 15K |
| StockData Score | ||
| Total score | 0 | 16 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 0 | 2 (better) |
| Performance score | 0 | 4 (better) |
| Health score | 0 | 6 (better) |
| Dividend score | 0 | 3 (better) |
| Valuation | ||
| P/E | – | 21.1× |
| P/S | – | 5.8× |
| P/B | – | 3.0× |
| EV/EBITDA | – | 17.0× |
| P/FCF | – | 25.8× |
| PEG | – | 7.63 |
| FCF yield | – | 3.9% |
| Fair value | – | $888.57 |
| Margin of safety | – | −7.5% |
| Growth | ||
| Revenue growth (TTM) | – | 18.6% |
| Revenue growth, 5Y average | – | 11.0% |
| Net income growth (TTM) | – | 5.2% |
| EPS growth (TTM) | – | 8.4% |
| EPS growth, 5Y average | – | 6.3% |
| Profitability | ||
| Operating margin | – | 28.8% |
| Net margin | – | 28.5% |
| FCF margin | – | 22.6% |
| Return on equity | – | 14.9% |
| Return on invested capital | – | 16.3% |
| Financial health | ||
| Debt / equity | – | 0.06 |
| Net debt / EBITDA | – | −1.36 |
| Interest coverage | – | 104× |
| Current ratio | – | 3.35 |
| Altman Z-score | – | 7.82 |
| Piotroski F-score | – | 5 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.39% |
| Payout ratio | – | 8.0% |
| Buyback yield | – | 2.0% |
| Shareholder yield | – | 2.4% |
| Ownership | ||
| Held by institutions | 79.5% | 88.5% |
| Held by insiders | 0.00% | 3.7% |
| Insider net buying, 12 months | – | −$57.4M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 2.2% |
Go deeper
- GMAB stock overview
- GMAB income statement
- GMAB valuation and score
- REGN stock overview
- REGN income statement
- REGN valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.